IXC Invex Therapeutics Ltd
Healthcare · Biotechnology
· website
$0.11
52wk 0.07 – 0.18
Overall
—
Value
—
Growth
—
Health
—
Quality
—
Momentum
—
Dividend
—
Price
About Invex Therapeutics Ltd
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase III clinical trial. The company has a collaboration with Tessara Therapeutics. Invex Therapeutics Ltd was incorporated in 2019 and is based in Subiaco, Australia.
Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$8.27M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
-0.01
Dividend yield
—
Payout ratio
0.0%
Beta
0.54
EV / EBITDA
—
Price / Book
1.80
ROE
-16.8%
Operating margin
-96,227.3%
Net margin
0.0%
Total cash
$12.17M
Total debt
$0
Current ratio
26.76
Debt / Equity
—
Free cash flow
$-1.05M
Avg volume
29,882
Latest annual results
(FY ending 30 Jun 2025)
- Revenue—
- Gross profit—
- Operating income-$951.22K
- Net income-$476.87K
- Diluted EPS-0.01
- Free cash flow-$652.57K
- Net debt-$5.38M